NCT07386171 (MUS-AS) is a NA clinical trial of Micro-Ultrasound (mUS) in Prostate Cancer, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What drugs are being tested in NCT07386171?

Interventions in NCT07386171: Micro-Ultrasound (mUS).

What condition does NCT07386171 study?

NCT07386171 studies Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques.

Is NCT07386171 still recruiting?

NCT07386171 is currently not yet recruiting. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT07386171: MUS-AS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance

Not yet recruiting NA Last updated 4 February 2026

What this trial tests

NA trial testing Micro-Ultrasound (mUS) in Prostate Cancer in 90 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
1 March 2027

1 June 2027

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	90
Start date	1 March 2026
Primary completion	1 March 2027
Estimated completion	1 June 2027
Sites	1 location across Canada

Drugs / interventions tested

Micro-Ultrasound (mUS)

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Active Surveillance for Prostate Cancer — all drugs for Active Surveillance for Prostate Cancer →
Imaging Techniques — all drugs for Imaging Techniques →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

Adults 45 to 75, male only, with Prostate Cancer or Active Surveillance for Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease. Multiparametric MRI (mpMRI) is widely used to guide diagnosis and follow-up, but it can miss clinically significant prostate cancer and may be limited by access, cost, and variability in interpretation. Micro-ultrasound is a high-resolution ultrasound technique that may improve real-time detection of suspicious prostate lesions using a standardized scoring system (PRI-MUS). The purpose of this study is to evaluate the diagnostic performance of micro-ultrasound for detecting clinically significant prostate cancer in men with negative or stable mpMRI findings, either at initial diagnosis or during active surveillance follow-up. Participants will undergo micro-ultrasound assessment of the prostate. Areas considered suspicious on micro-ultrasound may be targeted for biopsy, followed by systematic prostate sampling. Biopsy results will be used as the reference standard to determine whether clinically significant prostate cancer is present. The study will assess measures such as sensitivity, specificity, and predictive values of micro-ultrasound, as well as procedure-related complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07405879 — The Impact of Having a Tattoo on Fertility Treatment Outcome · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07386171 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07386171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing